News Focus
News Focus
Followers 35
Posts 1202
Boards Moderated 1
Alias Born 08/27/2000

Re: biopharm post# 279313

Tuesday, 11/22/2016 11:46:08 AM

Tuesday, November 22, 2016 11:46:08 AM

Post# of 347009

We shall see, muaybe PS targeting provides 109%+ better MOS and those Docetaxel arms will never likely never outperform again unless matched with PS Targeting



109%? How can that be with docetaxel, if the data mining has proved 70% less than placebo??. Also, it's been admitted that chemo is not a good combo for antiPs.. That has been an arguement of mine as well, how is it that exposing more immunosuppressive PS through the use of chemo provides more Bavi efficacy??

Here's a quote of mine for reference:

And what about the Chemo Combos that we've been force fed? This is fundamentally flawed, IMO. Inhibiting the immune system in order to gain more PS? Think about that.. more immunosuppressive PS in hopes to dock more Bavituximab? It should have been less is more, not more is better.. And we've, they've known what the data mining has told us years ago, and that is BINDING IS WEAK.


http://investorshub.advfn.com/boards/read_msg.aspx?message_id=126143864

So will chemo

All the best,
John

Disclaimer: Every post, and all my views are only speculative. Do not invest money or any other resources based on these post or opinions. Best of luck and do your own due diligence!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y